Clinical trials: Inclusion Body Myositis
Sporadic Inclusion Body Myositis
Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
The primary objective of the study is to evaluate the efficacy of REGN2477+REGN1033 in combination on total lean mass, as measured by Dual-energy X-ray absorptiometry (DXA) in patients with sporadic inclusion body myositis…
- Trial name
- NCT03710941
- Testing
- REGN2477+REGN1033
- Sponsor
- Regeneron Pharmaceuticals
Dermatomyositis, Inclusion Body Myositis
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
Inflammatory myopathies are a group of muscle diseases characterized by muscle weakness, high levels of muscle enzymes in the blood, and inflammation of the tissue surrounding muscle fibers (endomysium).
- Conditions
- Dermatomyositis, Inclusion Body Myositis, Polymyositis
- Trial name
- NCT00001261
- Testing
- Gamma Globulin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
- Trial name
- NCT06479863
- Testing
- Pozelimab/Cemdisiran
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Austin Neuromuscular Center
Dermatomyositis, Adult Polymyositis
Environmental Risk Factors for Myositis in Military Personnel
Background: Myositis is a rare disease in which the body s immune cells attack the muscle tissue. It can cause muscle weakness, swelling, and pain. It can develop in people with no history of muscle problems.
- Conditions
- Dermatomyositis, Adult Polymyositis, Inclusion Body Myositis, Myositis
- Trial name
- NCT01734369
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Inclusion Body Myositis
Arimoclomol in Sporadic Inclusion Body Myositis
Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age.
- Trial name
- NCT00769860
- Testing
- Arimoclomol
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Richard Barohn, MD
Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1)
Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders
The primary aim is to characterize the prevalence, severity and quality of musculoskeletal nociceptive pain in adult patients with neuromuscular disorders (NMD).
- Conditions
- Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2, Spinal Muscular Atrophy Type 3
- Trial name
- NCT04907162
- Testing
- Beck depression inventory fast screen, German Pain Inventory, Brief Pain Inventory
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- LMU Klinikum
Dermatomyositis, Polymyositis
Adult and Juvenile Myositis
This study will evaluate subjects with adult- and childhood-onset myositis to learn more about their cause and the immune system changes and medical problems associated with them.
- Conditions
- Dermatomyositis, Polymyositis, Inclusion Body Myositis
- Trial name
- NCT00017914
- Where
- 4 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Sporadic Inclusion Body Myositis, Inclusion Body Myositis
Sporadic Inclusion Body Myositis Natural History Study
This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total).
- Trial name
- INSPIRE-IBM (NCT05046821)
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, Irvine
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Inclusion Body Myositis
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
A multicenter, nonrandomized, open-label, uncontrolled clinical extension trial designed to compare the efficacy and safety of early versus delayed start of arimoclomol in the treatment of Inclusion Body Myositis (IBM)
- Trial name
- NCT04049097
- Testing
- Arimoclomol
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 121 people
- Sponsor
- ZevraDenmark
IBM, Inclusion Body Myositis
Establishing Muscle Impedance Parameters With Electrical Impedance Myography
The primary aim of this study is to assess the changes in the impedance parameters of muscles in inclusion body myositis (IBM) through electrical impedance myography (EIM), an emerging non-invasive electrodiagnostic technology.
- Trial name
- NCT03633318
- Testing
- electrical impedance myography (EIM)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Yale University
Polymyositis
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
This study assessed the efficacy, safety and tolerability of BAF312 administered orally in patients with clinically active polymyositis and also in patients with polymyositis who had shown inadequate response to corticosteroids…
- Trial name
- NCT01801917
- Testing
- BAF312
- Where
- 8 sites in United States, Canada and 4 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Inclusion Body Myositis
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
- Trial name
- NCT05721573
- Testing
- ABC008
- Where
- 45 sites in United States, Australia and 5 more
- Volunteers
- 272 people
- Sponsor
- Abcuro, Inc.
Sporadic Inclusion Body Myositis
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis
- Trial name
- NCT01423110
- Testing
- BYM338
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Inclusion Body Myositis
Lithium in Inclusion Body Myositis (IBM)
IBM is the most common acquired muscle disease occurring over the age of 50. The underlying cause remains unknown and there is currently no effective treatment.
- Trial name
- Li-IBM (NCT00917956)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Phoenix Neurological Associates, LTD
Myositis, Polymyositis
Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
Idiopathic inflammatory myopathies (IIM) are a great concern in acquired muscle illnesses. An appropriate and rapid diagnosis is necessary, because morbidity and mortality are high and a specific treatment is needed.
- Conditions
- Myositis, Polymyositis, Dermatomyositis, Myositis, Inclusion Body
- Trial name
- DARWIM (NCT01432613)
- Testing
- MRI-oriented muscle biopsy
- Where
- France
- Volunteers
- 139 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Inclusion Body Myositis
Molecular Profile of the Evolution of Inclusion Body Myositis
This study aims at assessing the gene expression in the muscles of patients suffering from sporadic Inclusion Body Myositis (sIBM) at various stages of the disease, by comparison with muscles of control subject.
- Trial name
- IBM-RNAseq (NCT03299335)
- Testing
- Blood collection
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Inclusion Body Myositis
Phase III Trial of Sirolimus in IBM
The hypothesis is that Sirolimus, (Rapamycin (R)) which is currently used in organ transplantation and works by blocking the activity of T effector cells but preserving T regulatory cells, as well as by inducing autophagy…
- Trial name
- NCT04789070
- Testing
- Sirolimus
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 140 people
- Sponsor
- University of Kansas Medical Center
Overweight and Obesity, Inflammation; Muscle
Influence of Aerobic Training and Weight Loss on Skeletal Muscle Inflammatory Markers and Muscle Protein Balance in Older Adults
It is estimated that 15% of adults aged 60-70 years, and up to 50% of adults aged 80 years and older are affected by sarcopenia-the age related loss of muscle mass and function.
- Conditions
- Overweight and Obesity, Inflammation; Muscle, Sedentary Lifestyle
- Trial name
- NCT03743675
- Testing
- Diet-Induced Weight Loss, Aerobic Exercise Training
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Miami University
Pain, Weakness
Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
This study will evaluate whether a dietary supplement, coenzyme Q10 (CoQ10), will improve muscle symptoms, such as muscle aches, pains, cramps, and/or weakness, which are experienced by some individuals who use statin medications.
- Conditions
- Pain, Weakness, Cramps, Myalgia or Myositis Nos
- Trial name
- NCT01032993
- Testing
- Coenzyme Q10
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Catherine Buettner